On Wednesday, Morgan Stanley resumed coverage on Genmab A/S (NASDAQ:) stock, assigning an Equalweight rating and establishing a price target of $31.00.
The firm’s analysis suggests that the biotech company’s stock has found a stable floor value in the upper $20s, which considers Genmab’s base of royalty and partnership economics. This foundation includes royalties from commercialized products such as Johnson & Johnson’s Darzalex, Novartis (SIX:)’ Kesimpta, and Amgen (NASDAQ:)’s Tepezza.
The firm noted that Genmab’s shares have experienced significant pressure year-to-date, declining over 10% compared to the Nasdaq Biotechnology Index (NBI), which has risen approximately 8% for the year.
The downward trend is believed to be influenced by a combination of factors, including uncertainty surrounding Johnson & Johnson’s decision on whether to opt-in for the next-generation CD38 asset GEN3014, unresolved questions about Genmab’s business development strategies to enhance its proprietary pipeline, and BioNTech (NASDAQ:)’s recent decision against continuing the development of acasunlimab (DuoBody-PD-L1 x 4-1BB).
The assessment by Morgan Stanley reflects a cautious stance on Genmab, taking into account the company’s upcoming pipeline decisions, particularly the GEN3014 opt-in decision from Johnson & Johnson, which remains uncertain. The Equalweight rating indicates that the firm perceives the company’s stock valuation as balanced at its current level.
Genmab’s late-stage pipeline value, which factors in products such as Rina-S and acasunlimab, is considered modestly risk-adjusted in Morgan Stanley’s valuation model. This model is a key element in determining the price target and rating for the company’s shares.
The coverage resumption by Morgan Stanley comes at a time when Genmab is navigating through significant pipeline developments and strategic decisions that could impact the company’s future growth and stock performance.
In other recent news, Genmab A/S, the biotechnology company, reported a robust financial performance for the first half of 2024 showing a 36% growth in revenue to over DKK 9.5 billion and a 29% increase in operating profit to DKK 2.4 billion. The company’s drugs, DARZALEX, KESIMPTA, and EPKINLY, significantly contributed to these figures.
In addition, Genmab announced a capital increase resulting from employee warrant exercises, though the specific number of warrants exercised and the amount of capital raised were not disclosed.
The European Commission granted approval for Genmab’s TEPKINLY® (epcoritamab) for the treatment of adults with relapsed or refractory follicular lymphoma, marking the second EC approval for TEPKINLY®. The approval is based on positive clinical trial results, demonstrating the efficacy of TEPKINLY® in patients who have previously undergone systemic therapy.
However, JPMorgan downgraded Genmab’s stock from Overweight to Neutral, citing a potential 15% to 22% downside to consensus 2025 and 2026 EBIT forecasts due to increases in operational expenditure. The firm also adjusted the price target for Genmab and placed the company’s shares on Negative Catalyst Watch.
These developments reflect Genmab’s continuous efforts in innovation and development in the pharmaceutical industry and its navigation of the regulatory landscape.
InvestingPro Insights
Genmab A/S (NASDAQ:GMAB) has been navigating a challenging market environment, as noted by Morgan Stanley’s recent coverage. To provide a more comprehensive view, InvestingPro data reveals a market capitalization of $17.59 billion, reflecting the company’s substantial presence in the biotechnology sector. The firm’s financial health is underscored by a robust P/E ratio of 21.97, which adjusts slightly to 21.32 for the last twelve months as of Q2 2024, indicating a reasonable valuation in relation to earnings.
Revenue growth remains a strong suit for Genmab, with a 17.19% increase over the last twelve months as of Q2 2024, and an even more impressive quarterly surge of 29.58%. This growth trajectory is complemented by a high gross profit margin of 96.95%, showcasing the company’s efficiency in converting sales into profit. Furthermore, with an operating income margin of 32.57%, Genmab demonstrates solid profitability in its operations.
InvestingPro Tips highlight that Genmab holds more cash than debt on its balance sheet and that management has been actively buying back shares, both of which could signal confidence in the company’s financial strategy and future prospects. Moreover, the fact that four analysts have revised their earnings upwards for the upcoming period can be seen as a positive indicator for potential investors. For those seeking further insights, there are an additional 10 InvestingPro Tips available, which can be found at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
